Kamui Pharma Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
7
Kamui Pharma General Information
Description
Developer of a drug discovery platform designed to develop probiotic medicines. The company's drug is used for the treatment of inflammatory bowel disease as it uses long-chain polyphosphoric acid derived from probiotics which helps to cure the diseases, enabling patients to avail of improved treatment.
Contact Information
Website
www.kamuipharma.co.jpCorporate Office
- Care of Asahikawa Medical University
- 1-1-1 Midorigaoka Higashi 2-jo
- Asahikawa, 078-8510
- Japan
Corporate Office
- Care of Asahikawa Medical University
- 1-1-1 Midorigaoka Higashi 2-jo
- Asahikawa, 078-8510
- Japan
Kamui Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 3. Later Stage VC | 01-Jan-2023 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series B) | 26-Jul-2022 | $4.76M | $6.83M | Completed | Generating Revenue | |
| 1. Seed Round | 10-May-2018 | $2.08M | $2.08M | Completed | Generating Revenue |
Kamui Pharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| B preferred | ||||||||
| A Preferred |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Kamui Pharma Patents
Kamui Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026014535-A1 | Composition for preventing or treating endometriosis | Pending | 11-Jul-2024 | ||
| WO-2026014534-A1 | Pharmaceutical composition for preventing or treating interstitial cystitis/bladder pain syndrome | Pending | 11-Jul-2024 | ||
| EP-4599833-A1 | Pharmaceutical composition containing zinc polyphosphate | Pending | 27-Oct-2022 | ||
| US-20260166076-A1 | Pharmaceutical composition containing zinc polyphosphate | Pending | 27-Oct-2022 | ||
| WO-2024090538-A1 | Pharmaceutical composition containing zinc polyphosphate | Inactive | 27-Oct-2022 | A61K33/42 |
Kamui Pharma Signals
Kamui Pharma Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| CEJ Capital | Corporate Venture Capital | Minority | ||
| Cyberdyne | Corporation | Minority | ||
| DG Ventures | Corporate Venture Capital | Minority | ||
| Angel (individual) | Minority | |||
| Hokkaido Venture Capital | Venture Capital | Minority |
Kamui Pharma FAQs
-
When was Kamui Pharma founded?
Kamui Pharma was founded in 2018.
-
Where is Kamui Pharma headquartered?
Kamui Pharma is headquartered in Asahikawa, Japan.
-
What is the size of Kamui Pharma?
Kamui Pharma has 10 total employees.
-
What industry is Kamui Pharma in?
Kamui Pharma’s primary industry is Drug Discovery.
-
Is Kamui Pharma a private or public company?
Kamui Pharma is a Private company.
-
What is Kamui Pharma’s current revenue?
The current revenue for Kamui Pharma is .
-
How much funding has Kamui Pharma raised over time?
Kamui Pharma has raised $7.17M.
-
Who are Kamui Pharma’s investors?
CEJ Capital, Cyberdyne, DG Ventures, , and Hokkaido Venture Capital are 5 of 7 investors who have invested in Kamui Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process